Browse related articlesBreast Cancer treatment now available in the UAE
United Arab Emirates: Monday, November 03 - 2008 at 12:41
Biotechnology companies NeoBiocon and Abraxis BioScience, have announced the launch of Abraxane in the UAE for the treatment of breast cancer. 'The launch of Abraxane in the UAE represents a major strategic step in our plan to provide safer and more effective cancer treatments,' said Patrick Soon-Shiong, MD, Chairman and Chief Executive Officer of Abraxis BioScience.
See Also
Also consider reading:
- » WHO to assist Qatar
- » Qatar shows highest diabetes rate
- » Health services 'failing' underprivileged
- » New medical residency medical centre to open in Dubai
- » UAE onboard UN body on tropical disease
- » GCC spend to quadruple
- » UAE approves HIV drug sales
- » Overall satisfaction with Dubai healthcare services, survey finds
- » Pregnant women urged to use 4D foetal scan
- » UAE diabetics to receive new treatment
Facebook
LinkedIn
Digg
StaffMonday, November 03 - 2008 at 12:41 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Disclaimer:
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
Web Feeds